Periodic Reporting for period 1 - LIBERATE (Blood Biomarker Array Technology)
Reporting period: 2015-07-01 to 2015-10-31
The LIBERATE Feasibility Study sought to identify the market opportunity and technological requirements for a rapid near-patient blood testing device for general diagnosis and health surveillance of a large and aging population. The instrument will be approximately the size of a credit card reader and perform 10-20 tests from 10 micolitres of blood in 10 minutes. The blood tests will be supported on a chip as a card into the instrument; single use for each patient. We consulted with UK primary care physicians (GPs) as to which tests would be most useful firstly as a general triage and surveillance of public health; a General Diagnosis Array (GDA). The GPs supported the concept of public health surveillance and identified a set of tests that would be most appropriate. From these responses and other consultations, the GDA would be used on 6% of all consultations, an indicative market size of €1.3bn annually in the UK. We also assessed the market for three other chips, a Blood Profile Array, a Liver Function and Kidney Function Array and a Metabolic Profile Array. These chips have markets size estimates of: €0.9bn €0.5bn and €0.5nbn respectively. The GDA market in the EU (scaling for population) would be €10.2bn.
The GP consultation established the value chain for the GDA identifying the current costs. Our estimates for the UK suggest this process costs €184 - €244 including all of the time to organise the logistics. The GDA will free up 20M GP second appointments annually, saving the NHS €2.1bn in addition to providing the patient with the tests results and care pathway at the first meeting.
Our initial set of tests confirmed by the GPs was: CRP, White Blood Cells, D-Dimer, Troponin I/T, C3 and C4. The results for CRP were completely successful with a CV of 5.2% compared with standard laboratory measurements. Development is on going for C3 (CV 18%) and C4, Troponin T/I, D-dimer where the results were qualitative.
The feasibility study has clearly demonstrated a market for a new vision of patient care - “Test and Treat the Patient” - which includes significant benefits to both to patient outcome and health economic advantages and the additional new idea of using the patient as their baseline. If normal-for-the-patient levels are known then small changes can be detected enabling a care pathway tailored for each patient to be managed, no matter where they are geographically. Our array technology will truly LIBERATE public healthcare.
The GP consultation established the value chain for the GDA identifying the current costs. Our estimates for the UK suggest this process costs €184 - €244 including all of the time to organise the logistics. The GDA will free up 20M GP second appointments annually, saving the NHS €2.1bn in addition to providing the patient with the tests results and care pathway at the first meeting.
Our initial set of tests confirmed by the GPs was: CRP, White Blood Cells, D-Dimer, Troponin I/T, C3 and C4. The results for CRP were completely successful with a CV of 5.2% compared with standard laboratory measurements. Development is on going for C3 (CV 18%) and C4, Troponin T/I, D-dimer where the results were qualitative.
The feasibility study has clearly demonstrated a market for a new vision of patient care - “Test and Treat the Patient” - which includes significant benefits to both to patient outcome and health economic advantages and the additional new idea of using the patient as their baseline. If normal-for-the-patient levels are known then small changes can be detected enabling a care pathway tailored for each patient to be managed, no matter where they are geographically. Our array technology will truly LIBERATE public healthcare.
Market Survey
GDA Specification for the GP Practice Market (Deliverable 1)
GDA assay bill of materials and protocol; (Deliverable 2)
The Health Economic Case for GP market usage (Deliverable 3)
Prototype Process assessment to deliver the CE-marked instrument – full cost (Deliverable 4)
The conclusion of the action – The Attomarker Business Plan (Deliverable 5)
GDA Specification for the GP Practice Market (Deliverable 1)
GDA assay bill of materials and protocol; (Deliverable 2)
The Health Economic Case for GP market usage (Deliverable 3)
Prototype Process assessment to deliver the CE-marked instrument – full cost (Deliverable 4)
The conclusion of the action – The Attomarker Business Plan (Deliverable 5)
